BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. More Details
Very undervalued with adequate balance sheet.
Share Price & News
How has BioMarin Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BMRN is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: BMRN's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: BMRN underperformed the US Biotechs industry which returned 31.5% over the past year.
Return vs Market: BMRN underperformed the US Market which returned 56.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is BioMarin Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDoes BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?
1 month ago | Simply Wall StThe BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price Has Gained 12% And Shareholders Are Hoping For More
2 months ago | Simply Wall StIs BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 21% Discount?
Is BioMarin Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMRN ($77.07) is trading below our estimate of fair value ($171.99)
Significantly Below Fair Value: BMRN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMRN is good value based on its PE Ratio (16.2x) compared to the US Biotechs industry average (29.9x).
PE vs Market: BMRN is good value based on its PE Ratio (16.2x) compared to the US market (22.3x).
Price to Earnings Growth Ratio
PEG Ratio: BMRN is good value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: BMRN is good value based on its PB Ratio (3.4x) compared to the US Biotechs industry average (3.9x).
How is BioMarin Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMRN's forecast earnings growth (16.7% per year) is above the savings rate (2%).
Earnings vs Market: BMRN's earnings (16.7% per year) are forecast to grow slower than the US market (18.6% per year).
High Growth Earnings: BMRN's earnings are forecast to grow, but not significantly.
Revenue vs Market: BMRN's revenue (15.9% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: BMRN's revenue (15.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMRN's Return on Equity is forecast to be low in 3 years time (11.5%).
How has BioMarin Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMRN has a high level of non-cash earnings.
Growing Profit Margin: BMRN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: BMRN has become profitable over the past 5 years, growing earnings by 68.6% per year.
Accelerating Growth: BMRN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BMRN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: BMRN's Return on Equity (20.9%) is considered high.
How is BioMarin Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: BMRN's short term assets ($2.3B) exceed its short term liabilities ($492.5M).
Long Term Liabilities: BMRN's short term assets ($2.3B) exceed its long term liabilities ($1.2B).
Debt to Equity History and Analysis
Debt Level: BMRN's debt to equity ratio (26.2%) is considered satisfactory.
Reducing Debt: BMRN's debt to equity ratio has reduced from 27.6% to 26.2% over the past 5 years.
Debt Coverage: BMRN's debt is not well covered by operating cash flow (7.9%).
Interest Coverage: Insufficient data to determine if BMRN's interest payments on its debt are well covered by EBIT.
What is BioMarin Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BMRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BMRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jean-Jacques Bienaime (67 yo)
Mr. Jean-Jacques Bienaime, MBA, serves as a Member of Strategic Advisory Board at Longwood Fund. He has been the Chief Executive Officer of Biomarin Pharmaceutical Inc. since June 2005. He served as Direct...
CEO Compensation Analysis
Compensation vs Market: Jean-Jacques's total compensation ($USD18.41M) is above average for companies of similar size in the US market ($USD10.98M).
Compensation vs Earnings: Jean-Jacques's compensation has been consistent with company performance over the past year.
Experienced Management: BMRN's management team is considered experienced (3.4 years average tenure).
Experienced Board: BMRN's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BioMarin Pharmaceutical Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BioMarin Pharmaceutical Inc.
- Ticker: BMRN
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$14.021b
- Shares outstanding: 181.83m
- Website: https://www.biomarin.com
Number of Employees
- BioMarin Pharmaceutical Inc.
- 770 Lindaro Street
- San Rafael
- United States
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products inclu...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/12 22:37|
|End of Day Share Price||2021/04/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.